Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial

Ayana T. Ruffin, Crystal L. Mallow, Brian M. Olson, Jacklyn Hammons, Brenda Melendez, Manoj Chelvanambi, Elaine M. Gersz, Megen C. Wittling, Laurence P. Diggs, Christine Reilly, Jeffrey M. Switchenko, Alexander J. Lazar, Shannon K. Swisher, Jayden Kim, Brian Burns, Agnes Harutyunyan, Terrence L. Fisher, Keith A. Delman, Melinda L. Yushak, Douglas C. Parker, David Lawson, Jennifer A. Wargo, Maurice Zauderer, Elizabeth E. Evans, Chrystal M. Paulos, Michael C. Lowe, Gregory B. Lesinski

Open source

DOI: 10.1038/s41467-026-78231-3
Published: 2026-10-06
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-78231-3,
  title = {Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial},
  author = {Ayana T. Ruffin and Crystal L. Mallow and Brian M. Olson and Jacklyn Hammons and Brenda Melendez and Manoj Chelvanambi and Elaine M. Gersz and Megen C. Wittling and Laurence P. Diggs and Christine Reilly and Jeffrey M. Switchenko and Alexander J. Lazar and Shannon K. Swisher and Jayden Kim and Brian Burns and Agnes Harutyunyan and Terrence L. Fisher and Keith A. Delman and Melinda L. Yushak and Douglas C. Parker and David Lawson and Jennifer A. Wargo and Maurice Zauderer and Elizabeth E. Evans and Chrystal M. Paulos and Michael C. Lowe and Gregory B. Lesinski},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-78231-3},
  url = {https://doi.org/10.1038/s41467-026-78231-3}
}

RIS

TY  - JOUR
TI  - Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
AU  - Ayana T. Ruffin
AU  - Crystal L. Mallow
AU  - Brian M. Olson
AU  - Jacklyn Hammons
AU  - Brenda Melendez
AU  - Manoj Chelvanambi
AU  - Elaine M. Gersz
AU  - Megen C. Wittling
AU  - Laurence P. Diggs
AU  - Christine Reilly
AU  - Jeffrey M. Switchenko
AU  - Alexander J. Lazar
AU  - Shannon K. Swisher
AU  - Jayden Kim
AU  - Brian Burns
AU  - Agnes Harutyunyan
AU  - Terrence L. Fisher
AU  - Keith A. Delman
AU  - Melinda L. Yushak
AU  - Douglas C. Parker
AU  - David Lawson
AU  - Jennifer A. Wargo
AU  - Maurice Zauderer
AU  - Elizabeth E. Evans
AU  - Chrystal M. Paulos
AU  - Michael C. Lowe
AU  - Gregory B. Lesinski
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-78231-3
UR  - https://doi.org/10.1038/s41467-026-78231-3
ER  -

APA

Ruffin, A. T., Mallow, C. L., Olson, B. M., Hammons, J., Melendez, B., Chelvanambi, M., Gersz, E. M., Wittling, M. C., Diggs, L. P., Reilly, C., Switchenko, J. M., Lazar, A. J., Swisher, S. K., Kim, J., Burns, B., Harutyunyan, A., Fisher, T. L., Delman, K. A., Yushak, M. L., Parker, D. C., Lawson, D., Wargo, J. A., Zauderer, M., Evans, E. E., Paulos, C. M., Lowe, M. C., & Lesinski, G. B. (2026). Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial. Nature Communications. https://doi.org/10.1038/s41467-026-78231-3

Source records

crossref · retrieved 2026-11-07T11:11:14.976Z